United States HR 5850: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Status: Referred to the Subcommittee on Health. (as of 2023-10-06)

State: United States · Session: 118 · Bill: HR 5850

Sponsors: Tracey Mann, John R. Moolenaar

View United States HR 5850 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.